O	0	4	Long
O	4	5	-
O	5	9	term
O	10	20	prevention
O	21	23	of
B-condition	24	32	skeletal
I-condition	33	46	complications
O	47	49	of
O	50	60	metastatic
O	61	67	breast
O	68	74	cancer
O	75	79	with
B-intervention	80	91	pamidronate
O	91	92	.

O	93	101	Protocol
O	102	104	19
O	105	111	Aredia
O	112	118	Breast
O	119	125	Cancer
O	126	131	Study
O	132	137	Group
O	137	138	.

O	139	150	Pamidronate
O	150	151	,
O	152	154	an
O	155	174	aminobisphosphonate
O	174	175	,
O	176	179	has
O	180	184	been
O	185	190	shown
O	191	193	to
O	194	199	lower
O	200	203	the
O	204	208	risk
O	209	211	of
O	212	220	skeletal
O	221	234	complications
O	235	245	associated
O	246	250	with
O	251	256	lytic
O	257	261	bone
O	262	269	lesions
O	270	273	for
O	274	276	up
O	277	279	to
O	280	281	1
O	282	286	year
O	287	289	in
O	290	295	women
O	296	300	with
O	301	306	stage
O	307	309	IV
O	310	316	breast
O	317	323	cancer
O	324	327	who
O	328	336	received
O	337	349	chemotherapy
O	349	350	.

O	351	353	We
O	354	361	studied
O	362	365	the
O	366	370	long
O	370	371	-
O	371	375	term
O	376	389	effectiveness
O	390	393	and
O	394	400	safety
O	401	403	of
O	404	413	continued
O	414	423	treatment
O	424	428	with
O	429	440	intravenous
O	441	452	pamidronate
O	453	462	infusions
O	463	466	for
O	467	469	up
O	470	472	to
O	473	474	2
O	475	480	years
O	480	481	.

B-total-participants	482	487	Three
I-total-participants	488	495	hundred
I-total-participants	496	502	eighty
I-total-participants	502	503	-
I-total-participants	503	506	two
O	507	512	women
O	513	517	with
O	518	528	metastatic
O	529	535	breast
O	536	542	cancer
O	543	546	and
O	547	552	lytic
O	553	557	bone
O	558	565	lesions
O	566	569	who
O	570	578	received
O	579	591	chemotherapy
O	592	596	were
O	597	605	randomly
O	606	614	assigned
O	615	617	to
O	618	625	receive
O	626	632	either
O	633	635	90
O	636	638	mg
O	639	641	of
O	642	653	pamidronate
O	654	656	or
B-control	657	664	placebo
O	665	678	intravenously
O	679	684	every
O	685	686	3
O	687	689	to
O	690	691	4
O	692	697	weeks
O	698	700	in
O	701	705	this
O	706	712	double
O	712	713	-
O	713	718	blind
O	718	719	,
O	720	731	multicenter
O	731	732	,
O	733	741	parallel
O	741	742	-
O	742	747	group
O	748	753	trial
O	753	754	.

O	755	763	Patients
O	764	768	were
O	769	778	evaluated
O	779	786	monthly
O	787	790	for
O	791	792	2
O	793	798	years
O	799	802	for
O	803	811	skeletal
O	812	825	complications
O	825	826	,
O	827	832	which
O	833	841	included
O	842	852	pathologic
O	853	862	fractures
O	862	863	,
O	864	868	need
O	869	872	for
O	873	882	radiation
O	883	885	or
O	886	893	surgery
O	894	896	to
O	897	902	treat
O	903	907	bone
O	908	921	complications
O	921	922	,
O	923	929	spinal
O	930	934	cord
O	935	946	compression
O	946	947	,
O	948	951	and
O	952	965	hypercalcemia
O	965	966	.

O	967	971	Bone
O	972	976	pain
O	976	977	,
O	978	987	analgesic
O	988	991	use
O	991	992	,
O	993	997	bone
O	998	1009	biochemical
O	1010	1017	markers
O	1017	1018	,
O	1019	1030	performance
O	1031	1037	status
O	1037	1038	,
O	1039	1046	quality
O	1047	1049	of
O	1050	1054	life
O	1054	1055	,
O	1056	1066	radiologic
O	1067	1075	response
O	1076	1078	in
O	1079	1083	bone
O	1083	1084	,
O	1085	1088	and
O	1089	1097	survival
O	1098	1102	were
O	1103	1107	also
O	1108	1117	evaluated
O	1117	1118	.

O	1119	1121	As
O	1122	1124	in
O	1125	1128	the
O	1129	1134	first
O	1135	1139	year
O	1140	1142	of
O	1143	1152	treatment
O	1152	1153	,
O	1154	1157	the
B-outcome	1158	1168	proportion
I-outcome	1169	1171	of
I-outcome	1172	1180	patients
I-outcome	1181	1185	with
I-outcome	1186	1189	any
I-outcome	1190	1198	skeletal
I-outcome	1199	1211	complication
O	1212	1215	was
O	1216	1229	significantly
O	1230	1234	less
O	1235	1238	for
O	1239	1242	the
O	1243	1254	pamidronate
O	1255	1259	than
O	1260	1263	the
O	1264	1271	placebo
O	1272	1277	group
O	1278	1280	at
O	1281	1283	15
O	1283	1284	,
O	1285	1287	18
O	1287	1288	,
O	1289	1291	21
O	1291	1292	,
O	1293	1296	and
O	1297	1299	24
O	1300	1306	months
O	1307	1308	(
O	1308	1309	P
O	1310	1311	<
O	1312	1313	.
O	1313	1316	001
O	1316	1317	)
O	1317	1318	.

O	1319	1322	The
O	1323	1334	proportions
O	1335	1337	of
B-outcome	1338	1346	patients
I-outcome	1347	1351	with
I-outcome	1352	1355	any
I-outcome	1356	1366	pathologic
I-outcome	1367	1375	fracture
O	1376	1377	(
O	1377	1378	i
O	1378	1379	.
O	1379	1380	e
O	1380	1381	.
O	1381	1382	,
O	1383	1392	vertebral
O	1393	1396	and
O	1397	1409	nonvertebral
O	1410	1419	fractures
O	1419	1420	)
O	1420	1421	,
B-outcome	1422	1426	need
I-outcome	1427	1430	for
I-outcome	1431	1440	radiation
I-outcome	1441	1443	or
I-outcome	1444	1451	surgery
I-outcome	1452	1454	to
I-outcome	1455	1460	treat
I-outcome	1461	1465	bone
I-outcome	1466	1479	complications
I-outcome	1479	1480	,
I-outcome	1481	1484	and
I-outcome	1485	1498	hypercalcemia
O	1499	1503	were
O	1504	1508	also
O	1509	1522	statistically
O	1523	1527	less
O	1528	1531	for
O	1532	1535	the
O	1536	1547	pamidronate
O	1548	1552	than
O	1553	1556	the
O	1557	1564	placebo
O	1565	1570	group
O	1570	1571	.

O	1572	1575	The
B-outcome	1576	1582	median
I-outcome	1583	1587	time
I-outcome	1588	1590	to
I-outcome	1591	1594	the
I-outcome	1595	1600	first
I-outcome	1601	1609	skeletal
I-outcome	1610	1622	complication
O	1623	1626	was
B-iv-cont-median	1627	1629	13
I-iv-cont-median	1629	1630	.
I-iv-cont-median	1630	1631	9
I-iv-cont-median	1632	1638	months
O	1639	1641	in
O	1642	1645	the
O	1646	1657	pamidronate
O	1657	1658	-
O	1658	1665	treated
O	1666	1671	women
O	1672	1675	and
B-cv-cont-median	1676	1677	7
I-cv-cont-median	1677	1678	.
I-cv-cont-median	1678	1679	0
I-cv-cont-median	1680	1686	months
O	1687	1689	in
O	1690	1693	the
O	1694	1701	placebo
O	1702	1707	group
O	1708	1709	(
O	1709	1710	P
O	1711	1712	<
O	1713	1714	.
O	1714	1717	001
O	1717	1718	)
O	1718	1719	.

O	1720	1724	Long
O	1724	1725	-
O	1725	1729	term
O	1730	1739	treatment
O	1740	1743	did
O	1744	1747	not
O	1748	1754	result
O	1755	1757	in
O	1758	1761	any
O	1762	1772	unexpected
B-outcome	1773	1780	adverse
I-outcome	1781	1787	events
O	1787	1788	.

B-outcome	1789	1797	Survival
O	1798	1801	did
O	1802	1805	not
O	1806	1812	differ
O	1813	1820	between
O	1821	1824	the
O	1825	1828	two
O	1829	1835	groups
O	1835	1836	.

O	1837	1840	The
O	1841	1845	risk
O	1846	1849	for
O	1850	1860	osteolytic
O	1861	1865	bone
O	1866	1872	lesion
O	1873	1886	complications
O	1887	1889	in
O	1890	1900	metastatic
O	1901	1907	breast
O	1908	1914	cancer
O	1915	1918	was
O	1919	1932	significantly
O	1933	1942	decreased
O	1943	1947	with
O	1948	1955	monthly
O	1956	1965	infusions
O	1966	1968	of
O	1969	1971	90
O	1972	1974	mg
O	1975	1977	of
O	1978	1989	pamidronate
O	1989	1990	,
O	1991	1994	and
O	1995	1999	this
O	2000	2006	effect
O	2007	2010	was
O	2011	2021	maintained
O	2022	2025	for
O	2026	2028	at
O	2029	2034	least
O	2035	2036	2
O	2037	2042	years
O	2042	2043	.

O	2044	2055	Pamidronate
O	2056	2058	is
O	2059	2060	a
O	2061	2067	useful
O	2068	2075	adjunct
O	2076	2078	to
O	2079	2087	standard
O	2088	2100	chemotherapy
O	2101	2103	in
O	2104	2107	the
O	2108	2118	palliative
O	2119	2128	treatment
O	2129	2131	of
O	2132	2142	metastatic
O	2143	2149	breast
O	2150	2156	cancer
O	2156	2157	.
